Status:
COMPLETED
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Myeloproliferative Disorders
Eligibility:
All Genders
18+ years
Brief Summary
The main goal of the study is to progress in our understanding of the molecular basis of myeloproliferative disorders of the bone marrow (polycythemia vera, essential thrombocythemia, primary myelofib...
Detailed Description
Myeloproliferative disorders (MPD) are rare malignant diseases of the bone marrow characterized by a proliferation of differentiated blood cells during a long time and a possible transformation in an ...
Eligibility Criteria
Inclusion
- Patients affected with polycythemia vera, essential thrombocythemia or primary myelofibrosis
- Familial cases
- Subjects above 18 years old
- Non affected controls
Exclusion
- patients with chronic myeloid leukaemia
- subjects under 18 years old
Key Trial Info
Start Date :
September 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
234 Patients enrolled
Trial Details
Trial ID
NCT00873574
Start Date
September 1 2008
End Date
September 1 2012
Last Update
March 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology, Hospital Saint Antoine
Paris, France, 75012